Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447903 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447849 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447865 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447867 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4973797 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447801 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447877 | 1.00 | CDC25A (0.56) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447869 | 0.98 | CDC25A (0.57) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447889 | 0.98 | CDC25A (0.57) | CDC25ALPAR3LPAR2LPAR1LMNA | |
| SCHEMBL14447872 | 0.92 | LPAR3 (0.52) | CDC25ALPAR3LPAR2LPAR1P2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962862-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEROF | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ZENTARIS GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ZENTARIS GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| WO-2007071658-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071658-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1800684-A1 | Novel alkyl phospholipid derivatives and uses thereof | Zentaris GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | PHOSPHO1, PTDSS1, PTDSS2 | CDC25A 442/4885LPAR3 82/4885LPAR2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.